A meta-analysis evaluating the efficacy of liraglutide in reducing cardiovascular complications among patients with type 2 diabetes
- Author:
Michelle P. Del Rosario
1
;
Celeste Ong-Ramos
1
Author Information
- Publication Type:Meta-Analysis
- Keywords: GLP-1 Agonist; Major Adverse Cardiovascular Events; Cardiovascular Complications
- MeSH: Human; Liraglutide; Diabetes Mellitus, Type 2
- From: Philippine Journal of Internal Medicine 2025;63(4):93-101
- CountryPhilippines
- Language:English
-
Abstract:
BACKGROUND:The objective of this study was to determine the efficacy of liraglutide in reducing cardiovascular complications.
METHODOLOGY:Literature searches of electronic databases (PubMed and ScienceDirect) were performed to identify relevant studies. Relevant journals included were electronically searched for randomized controlled trials (RCTs) regarding the use of liraglutide versus placebo in reducing the rate of cardiovascular complications. Data extraction and quality assess- ment were done by independent reviewers. Statistical analysis of the study was accomplished using Cochrane Systematic Review Software Review Manager. Mean difference was used to analyze a data set which used mean and standard deviation from the studies. A p-value of less than 0.05 for the observed effect size was considered statistically significant.
RESULTS:A total of two RCTs with 16,977 patients were included in this meta-analysis. The results showed that in the lirag- lutide group, there is a statistically lower rate of the major adverse cardiovascular events (risk ratio [RR] 0.86 [0.78, 0.95]), cardiovascular events (RR 0.75 [0.63, 0.89]), and all-cause mortality (RR 0.81 [0.70, 0.93), but it is not statistically significant when compared to the placebo group in terms of non-fatal myocardial infarction and non-fatal stroke. There is no significant difference in rates of severe adverse events in general (p > 0.05). However, liraglutide caused significant reduction in rates of severe hypoglycemia as an independent secondary outcome (p < 0.05).
CONCLUSION:Compared with placebo, liraglutide provided a significant reduction in MACE, cardiovascular events, all-cause mortality and severe hypoglycemia as an adverse event. - Full text:202606301554345458313-2024-342.pdf
